<DOC>
	<DOCNO>NCT00451880</DOCNO>
	<brief_summary>The purpose study determine safe dose multiple Raf kinase inhibitor ( include c-Raf , B-Raf , activate mutant B-RafV600E ) XL281 , often take , well subject cancer tolerate XL281 . This study also determine body reacts XL281 take without food , without Pepcid ( famotidine ) , drug inhibits stomach acid production .</brief_summary>
	<brief_title>Study XL281 Adults With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Famotidine</mesh_term>
	<criteria>Key The subject histologically confirm solid tumor metastatic unresectable , standard curative palliative measure exist longer effective , therapy know prolong survival . Subjects treat MTD ( twice daily ) must diagnosis colorectal cancer , nonsmallcell lung cancer ( longer recruit ) , melanoma , papillary thyroid cancer . Certain eligibility requirement must also meet . The subject ≥18 year old . The subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 . The subject adequate organ marrow function . The subject capable understanding protocol sign informed consent document . Sexually active subject ( male female ) must use medically acceptable method contraception course study 3 month study drug discontinuation . Female subject childbearing potential must negative pregnancy test screening . The subject diagnosis malignancy ( unless nonmelanoma skin cancer , carcinoma situ cervix , malignancy diagnose ≥5 year ago , evidence disease 5 year prior screen study ) . The subject must meet certain eligibility requirement . Key The subject receive anticancer treatment ( eg , chemotherapy , radiotherapy , cytokine , hormone ) within 28 day ( 6 week nitrosoureas mitomycin C ) first dose study drug . The subject receive treatment small molecule kinase inhibitor hormonal therapy ( include investigational kinase inhibitor hormone ) within certain amount time first dose study drug . The subject receive investigational agent within 28 day first dose XL281 . The subject recover Grade ≤1 adverse event ( AEs ) within 10 % baseline value due investigational agent administer 30 day prior study enrollment . Some irreversible toxicity previous treatment may allow . The subject require treatment antacid ( continual treatment ) , proton pump inhibitor , H2 receptor antagonist . The subject primary brain tumor know brain metastasis . The subject uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . The subject pregnant breastfeeding . The subject know positive human immunodeficiency virus ( HIV ) . The subject allergy hypersensitivity component XL281 formulation famotidine . The subject unable unwilling abide study protocol cooperate fully investigator designee . The subject receive anticoagulation warfarin coumarinrelated compound ( lowdose warfarin ≤ 1 mg/day , heparin , lowmolecular weight heparin permit ) The subject must meet certain eligibility requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>NSCLC</keyword>
</DOC>